INTERIM REPORT Q3 2020
Summary Financial overview July 1 – September 30, 2020 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 383.4 M (loss: 189.8) · Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) · On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significant events during the period July 1 – September 30, 2020 · The FDA granted priority review of melflufen for patients with triple-class refractory multiple myeloma and set the PDUFA date to February 28, 2021 · Patient enrolment in the pivotal phase 3 OCEAN study